Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 6, 2012

View Archived Issues

Phase Ib/IIa study of ISIS-SMNRx commences

Biogen Idec and Sobi report topline results from phase III A-LONG trial

Preliminary results demonstrate good safety and efficacy for 3F8 + NK cells in neuroblastoma

Omeros begins enrollment in phase I trial evaluating OMS-824

Dynavax to begin phase I studies of TLR9 agonist for asthma

Portola, Bristol-Myers Squibb and Pfizer sign collaboration agreement

Navidea Biopharmaceuticals resubmits Lymphoseek NDA

Lilly Japan and Chugai to terminate Evista comarketing agreement in Japan

FDA approves Xarelto for use in three new indications

Addex reports topline data from second part of phase IIa ADX-71149 study

European authorities accept Ferring's MAA for MVDS in induction of labor

Biomedical Catalyst awards grants for development of healthcare technologies

PDA-001 induces clinical response in patients with Crohn's disease

Tesaro commences first clinical trial of its ALK inhibitor

[18F]-FE-PE2I investigated in healthy controls and patients with Parkinson's disease

Maresin 1 demonstrates analgesic activity

Vardenafil rescues CFTR function across rectal mucosa

New immunosuppressive compounds presented by Chinese researchers

Chinese group patents novel antipsychotic agents

Progress of EXC-001 triggers payment to Isis Pharmaceuticals

Bayer Schering Pharma synthesizes new protein kinase inhibitors

Siena Biotech presents new Wnt signaling inhibitors

Antitope to develop new biologic ANT-2034 for multiple sclerosis

Bioniche Life Sciences discontinues phase III Urocidin trial

Votubia obtains European approval for TSC-associated renal angiomyolipoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...